Market capitalization | $1.67b |
Enterprise Value | $1.12b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3,749.20 |
P/S ratio (TTM) P/S ratio | 5,552.80 |
P/B ratio (TTM) P/B ratio | 3.21 |
Revenue growth (TTM) Revenue growth | -12.97% |
Revenue (TTM) Revenue | $300.00k |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
17 Analysts have issued a Viridian Therapeutics Inc forecast:
17 Analysts have issued a Viridian Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.30 0.30 |
14%
14%
|
|
Gross Profit | -1.27 -1.27 |
-
|
|
EBITDA | -281 -281 |
22%
22%
|
EBIT (Operating Income) EBIT | -283 -283 |
22%
22%
|
Net Profit | -257 -257 |
19%
19%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma; and remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.
Head office | United States |
CEO | Stephen Mahoney |
Employees | 96 |
Founded | 2006 |
Website | www.viridiantherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.